Please assess the completion status of the following clinical trial:

Trial Title: Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients between (and including) ages 18-70 and taking at least 5 mg/day of prednisone equivalents for at least 3 months and anticipating continued treatment at the same dose for at least 20 additional weeks will be eligible for enrollment.~Exclusion Criteria:~* Patients with a history of allergic reaction or other contraindication to memantine therapy or with other unstable medical conditions (e.g. recent myocardial infarction, diabetes with poor glycemic control) will not be allowed to participate.~* Pregnant or nursing women or women of childbearing age who will not use University of Texas Southwestern (UTSW) Institutional Review Board (IRB) approved methods of avoiding pregnancy will be excluded from the study.~* Those with a history of mental retardation, dementia, or other severe cognitive disorders will also be excluded from the study.~* Patients with baseline RAVLT total words recalled normative score \> 55 will be excluded to avoid including persons with exceptionally good declarative memory at baseline.~* Subjects who do not speak English will be excluded because many of the outcome measures used in this study are not validated in languages other than English.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).